ARHGEF19

Across TCGA pan-cancer cohorts, ARHGEF19 RNA is linked to patient survival in 20 of 34 cancer types, making it the most broadly survival-associated ARHGEF19 data layer compared with 5 for mutation status and 2 for mass-spec protein.

The strongest signal is observed in mesothelioma (MESO), where higher ARHGEF19 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated ARHGEF19 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LUAD show a favorable association.

MESO, KIRC, and HNSC are the cancer types where ARHGEF19 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	OS	Tertile	All	0.365	0.654	<.001	78	view →
KIRC	DFS	Quartile	All	0.716	0.851	<.001	67	view →
HNSC	DFS	Median	IV	0.724	0.559	.001	56	view →
LGG	DFS	Median	All	0.319	0.485	<.001	54	view →
LUAD	OS	Quartile	II,III,IV	0.779	0.603	.002	45	view →
KICH	OS	Median	All	0.826	1.000	.009	28	view →
UVM	DFS	Median	II,III,IV	0.434	0.789	.020	21	view →
LIHC	OS	Quartile	II,III,IV	0.380	0.713	.002	20	view →
ESCA	OS	Median	II,III,IV	0.812	0.608	.001	17	view →
SCLC	DFS	Tertile	All	0.988	0.477	.005	10	view →
THCA	DFS	Quartile	IV	0.458	0.910	.007	9	view →
ACC	DFS	Quartile	III,IV	0.786	0.108	.012	8	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 20 lineages.

ARHGEF19–MESO (OS)

Open the MESO breakdown →